Fig. 3From: A randomized, double-blind, placebo-controlled investigation of BCc1 nanomedicine effect on survival and quality of life in metastatic and non-metastatic gastric cancer patientsa Kaplan–Meier diagram of survival. b Hazard function diagram in metastatic patients (Lifetime tables of hazard and survival for patients who received BCc1 nanomedicine show a higher survival and lower hazard than patients who received placebo)Back to article page